Search research articles
Contact Us
Filters
Showing results (131-140 of 208) with videos related to
Page
of 21
Sort By:
Lung Cancer (Amsterdam, Netherlands)
|
January 22, 2026
Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)
Adam Barsouk, Alec Heidlauf, Keshav Goel, et al.
The British Journal of Radiology
|
October 11, 2019
Risk of post-operative, pre-radiotherapy contralateral neck recurrence in patients treated with surgery followed by adjuvant radiotherapy for human papilloma virus-associated tonsil cancer
Jared Gershowitz, Hann-Hsiang Chao, Abigail Doucette, et al.
The Oncologist
|
May 15, 2023
A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer
Charu Aggarwal, Alisha P Maity, Joshua M Bauml, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 13, 2024
Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)treated with osimertinib (osi) vs. Afatinib or erlotinib
Adam Barsouk, Omar Elghawy, Alec Heidlauf, et al.
International Journal of Particle Therapy
|
November 28, 2019
Quality of Life of Postoperative Photon versus Proton Radiation Therapy for Oropharynx Cancer
Sonam Sharma, Olivia Zhou, Reid Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 11, 2008
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study
Ezra E W Cohen, Lee S Rosen, Everett E Vokes, et al.
Clinical Lung Cancer
|
December 6, 2020
Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy
Lova Sun, Christiana W Davis, Wei-Ting Hwang, et al.
JCO Precision Oncology
|
February 16, 2019
Influence of <i>TP53</i> Mutation on Survival in Patients With Advanced <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer
Charu Aggarwal, Christiana W Davis, Rosemarie Mick, et al.
The Laryngoscope
|
June 2, 2021
Locoregional Recurrence in p16-Positive Oropharyngeal Squamous Cell Carcinoma After TORS
Ryan M Carey, Robert M Brody, David Shimunov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 2, 2015
Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors
John Sarantopoulos, Geoffrey I Shapiro, Roger B Cohen, et al.
Page
of 21
Search research articles
Search
Showing results (131-140 of 208) with videos related to
Sort By:
Page
of 21
Lung Cancer (Amsterdam, Netherlands)
|
January 22, 2026
Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)
Adam Barsouk, Alec Heidlauf, Keshav Goel, et al.
The British Journal of Radiology
|
October 11, 2019
Risk of post-operative, pre-radiotherapy contralateral neck recurrence in patients treated with surgery followed by adjuvant radiotherapy for human papilloma virus-associated tonsil cancer
Jared Gershowitz, Hann-Hsiang Chao, Abigail Doucette, et al.
The Oncologist
|
May 15, 2023
A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer
Charu Aggarwal, Alisha P Maity, Joshua M Bauml, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 13, 2024
Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)treated with osimertinib (osi) vs. Afatinib or erlotinib
Adam Barsouk, Omar Elghawy, Alec Heidlauf, et al.
International Journal of Particle Therapy
|
November 28, 2019
Quality of Life of Postoperative Photon versus Proton Radiation Therapy for Oropharynx Cancer
Sonam Sharma, Olivia Zhou, Reid Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 11, 2008
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study
Ezra E W Cohen, Lee S Rosen, Everett E Vokes, et al.
Clinical Lung Cancer
|
December 6, 2020
Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy
Lova Sun, Christiana W Davis, Wei-Ting Hwang, et al.
JCO Precision Oncology
|
February 16, 2019
Influence of <i>TP53</i> Mutation on Survival in Patients With Advanced <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer
Charu Aggarwal, Christiana W Davis, Rosemarie Mick, et al.
The Laryngoscope
|
June 2, 2021
Locoregional Recurrence in p16-Positive Oropharyngeal Squamous Cell Carcinoma After TORS
Ryan M Carey, Robert M Brody, David Shimunov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 2, 2015
Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors
John Sarantopoulos, Geoffrey I Shapiro, Roger B Cohen, et al.
Page
of 21